APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1 and PD-L1 Inhibitors

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

Selected research

Market Analysis & Forecast

Global PD-1 and PD-L1 Inhibitors Market Analysis and Forecast 2026-2032

30 December 2025193 pages

Choose your research edition.

Industry ResearchPD-1 and PD-L1 Inhibitors Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1 and PD-L1 Inhibitors Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal PD-1 and PD-L1 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1 and PD-L1 Inhibitors Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1 and PD-L1 Inhibitors Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.

This report presents an overview of global market for PD-1 and PD-L1 Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

Read the full market overview

This report researches the key producers of PD-1 and PD-L1 Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for PD-1 and PD-L1 Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the PD-1 and PD-L1 Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global PD-1 and PD-L1 Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for PD-1 and PD-L1 Inhibitors sales, projected growth trends, production technology, application and end-user industry.

PD-1 and PD-L1 Inhibitors Segment by Company

Merck

Bristol-Myers Squibb

Roche

AstraZeneca

Ono Pharmaceutical

Regeneron

Innovent

Hengrui Medicine

Junshi Biosciences

Merck KGaA

PD-1 and PD-L1 Inhibitors Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

PD-1 and PD-L1 Inhibitors Segment by Application

Solid Tumors

Blood-related Tumors

PD-1 and PD-L1 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of PD-1 and PD-L1 Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of PD-1 and PD-L1 Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-1 and PD-L1 Inhibitors sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. PD-1 Inhibitors Major Manufacturers Table 3. PD-L1 Inhibitors Major Manufacturers Table 4. Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Solid Tumors Major Manufacturers Table 6. Blood-related Tumors Major Manufacturers Table 7. PD-1 and PD-L1 Inhibitors Industry Trends Table 8. PD-1 and PD-L1 Inhibitors Industry Drivers Table 9. PD-1 and PD-L1 Inhibitors Industry Opportunities and Challenges Table 10. PD-1 and PD-L1 Inhibitors Industry Restraints Table 11. Global PD-1 and PD-L1 Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global PD-1 and PD-L1 Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 13. Global PD-1 and PD-L1 Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 14. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2021-2026) Table 15. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2027-2032) Table 16. Global PD-1 and PD-L1 Inhibitors Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (L) Table 17. Global PD-1 and PD-L1 Inhibitors Sales by Region (2021-2026) & (L) Table 18. Global PD-1 and PD-L1 Inhibitors Sales by Region (2027-2032) & (L) Table 19. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2021-2026) Table 20. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2027-2032) Table 21. Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 23. Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Manufacturers (2021-2026) Table 25. Global PD-1 and PD-L1 Inhibitors Sales Price (USD/ml) of Manufacturers (2021-2026) Table 26. Global PD-1 and PD-L1 Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global PD-1 and PD-L1 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global PD-1 and PD-L1 Inhibitors Manufacturers, Product Type & Application Table 29. Global PD-1 and PD-L1 Inhibitors Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global PD-1 and PD-L1 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global PD-1 and PD-L1 Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 34. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 35. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2021-2026) Table 36. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2027-2032) Table 37. Global PD-1 and PD-L1 Inhibitors Sales by Type 2021 VS 2025 VS 2032 (L) Table 38. Global PD-1 and PD-L1 Inhibitors Sales by Type (2021-2026) & (L) Table 39. Global PD-1 and PD-L1 Inhibitors Sales by Type (2027-2032) & (L) Table 40. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2021-2026) Table 41. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2027-2032) Table 42. Global PD-1 and PD-L1 Inhibitors Price by Type (2021-2026) & (USD/ml) Table 43. Global PD-1 and PD-L1 Inhibitors Price by Type (2027-2032) & (USD/ml) Table 44. Global PD-1 and PD-L1 Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 46. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 47. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2021-2026) Table 48. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2027-2032) Table 49. Global PD-1 and PD-L1 Inhibitors Sales by Application 2021 VS 2025 VS 2032 (L) Table 50. Global PD-1 and PD-L1 Inhibitors Sales by Application (2021-2026) & (L) Table 51. Global PD-1 and PD-L1 Inhibitors Sales by Application (2027-2032) & (L) Table 52. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2021-2026) Table 53. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2027-2032) Table 54. Global PD-1 and PD-L1 Inhibitors Price by Application (2021-2026) & (USD/ml) Table 55. Global PD-1 and PD-L1 Inhibitors Price by Application (2027-2032) & (USD/ml) Table 56. Merck Company Information Table 57. Merck Business Overview Table 58. Merck PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 59. Merck PD-1 and PD-L1 Inhibitors Product Portfolio Table 60. Merck Recent Development Table 61. Bristol-Myers Squibb Company Information Table 62. Bristol-Myers Squibb Business Overview Table 63. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 64. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio Table 65. Bristol-Myers Squibb Recent Development Table 66. Roche Company Information Table 67. Roche Business Overview Table 68. Roche PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 69. Roche PD-1 and PD-L1 Inhibitors Product Portfolio Table 70. Roche Recent Development Table 71. AstraZeneca Company Information Table 72. AstraZeneca Business Overview Table 73. AstraZeneca PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 74. AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio Table 75. AstraZeneca Recent Development Table 76. Ono Pharmaceutical Company Information Table 77. Ono Pharmaceutical Business Overview Table 78. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 79. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio Table 80. Ono Pharmaceutical Recent Development Table 81. Regeneron Company Information Table 82. Regeneron Business Overview Table 83. Regeneron PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 84. Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio Table 85. Regeneron Recent Development Table 86. Innovent Company Information Table 87. Innovent Business Overview Table 88. Innovent PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 89. Innovent PD-1 and PD-L1 Inhibitors Product Portfolio Table 90. Innovent Recent Development Table 91. Hengrui Medicine Company Information Table 92. Hengrui Medicine Business Overview Table 93. Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 94. Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio Table 95. Hengrui Medicine Recent Development Table 96. Junshi Biosciences Company Information Table 97. Junshi Biosciences Business Overview Table 98. Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 99. Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio Table 100. Junshi Biosciences Recent Development Table 101. Merck KGaA Company Information Table 102. Merck KGaA Business Overview Table 103. Merck KGaA PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2021-2026) Table 104. Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio Table 105. Merck KGaA Recent Development Table 106. North America PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 107. North America PD-1 and PD-L1 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 108. North America PD-1 and PD-L1 Inhibitors Sales by Type (2021-2026) & (L) Table 109. North America PD-1 and PD-L1 Inhibitors Sales by Type (2027-2032) & (L) Table 110. North America PD-1 and PD-L1 Inhibitors Sales Price by Type (2021-2026) & (USD/ml) Table 111. North America PD-1 and PD-L1 Inhibitors Sales Price by Type (2027-2032) & (USD/ml) Table 112. North America PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 113. North America PD-1 and PD-L1 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 114. North America PD-1 and PD-L1 Inhibitors Sales by Application (2021-2026) & (L) Table 115. North America PD-1 and PD-L1 Inhibitors Sales by Application (2027-2032) & (L) Table 116. North America PD-1 and PD-L1 Inhibitors Sales Price by Application (2021-2026) & (USD/ml) Table 117. North America PD-1 and PD-L1 Inhibitors Sales Price by Application (2027-2032) & (USD/ml) Table 118. North America PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. North America PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 120. North America PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 121. North America PD-1 and PD-L1 Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (L) Table 122. North America PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 123. North America PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 124. North America PD-1 and PD-L1 Inhibitors Sales Price by Country (2021-2026) & (USD/ml) Table 125. North America PD-1 and PD-L1 Inhibitors Sales Price by Country (2027-2032) & (USD/ml) Table 126. United States PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 127. Canada PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 128. Mexico PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 129. Europe PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 130. Europe PD-1 and PD-L1 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 131. Europe PD-1 and PD-L1 Inhibitors Sales by Type (2021-2026) & (L) Table 132. Europe PD-1 and PD-L1 Inhibitors Sales by Type (2027-2032) & (L) Table 133. Europe PD-1 and PD-L1 Inhibitors Sales Price by Type (2021-2026) & (USD/ml) Table 134. Europe PD-1 and PD-L1 Inhibitors Sales Price by Type (2027-2032) & (USD/ml) Table 135. Europe PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 136. Europe PD-1 and PD-L1 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 137. Europe PD-1 and PD-L1 Inhibitors Sales by Application (2021-2026) & (L) Table 138. Europe PD-1 and PD-L1 Inhibitors Sales by Application (2027-2032) & (L) Table 139. Europe PD-1 and PD-L1 Inhibitors Sales Price by Application (2021-2026) & (USD/ml) Table 140. Europe PD-1 and PD-L1 Inhibitors Sales Price by Application (2027-2032) & (USD/ml) Table 141. Europe PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. Europe PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 143. Europe PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 144. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (L) Table 145. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 146. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 147. Europe PD-1 and PD-L1 Inhibitors Sales Price by Country (2021-2026) & (USD/ml) Table 148. Europe PD-1 and PD-L1 Inhibitors Sales Price by Country (2027-2032) & (USD/ml) Table 149. Germany PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 150. France PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 151. U.K. PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 152. Italy PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 153. Russia PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 154. Spain PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 155. Netherlands PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 156. Switzerland PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 157. Sweden PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 158. Poland PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 159. China PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 160. China PD-1 and PD-L1 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 161. China PD-1 and PD-L1 Inhibitors Sales by Type (2021-2026) & (L) Table 162. China PD-1 and PD-L1 Inhibitors Sales by Type (2027-2032) & (L) Table 163. China PD-1 and PD-L1 Inhibitors Sales Price by Type (2021-2026) & (USD/ml) Table 164. China PD-1 and PD-L1 Inhibitors Sales Price by Type (2027-2032) & (USD/ml) Table 165. China PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 166. China PD-1 and PD-L1 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 167. China PD-1 and PD-L1 Inhibitors Sales by Application (2021-2026) & (L) Table 168. China PD-1 and PD-L1 Inhibitors Sales by Application (2027-2032) & (L) Table 169. China PD-1 and PD-L1 Inhibitors Sales Price by Application (2021-2026) & (USD/ml) Table 170. China PD-1 and PD-L1 Inhibitors Sales Price by Application (2027-2032) & (USD/ml) Table 171. Asia PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 172. Asia PD-1 and PD-L1 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 173. Asia PD-1 and PD-L1 Inhibitors Sales by Type (2021-2026) & (L) Table 174. Asia PD-1 and PD-L1 Inhibitors Sales by Type (2027-2032) & (L) Table 175. Asia PD-1 and PD-L1 Inhibitors Sales Price by Type (2021-2026) & (USD/ml) Table 176. Asia PD-1 and PD-L1 Inhibitors Sales Price by Type (2027-2032) & (USD/ml) Table 177. Asia PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 178. Asia PD-1 and PD-L1 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 179. Asia PD-1 and PD-L1 Inhibitors Sales by Application (2021-2026) & (L) Table 180. Asia PD-1 and PD-L1 Inhibitors Sales by Application (2027-2032) & (L) Table 181. Asia PD-1 and PD-L1 Inhibitors Sales Price by Application (2021-2026) & (USD/ml) Table 182. Asia PD-1 and PD-L1 Inhibitors Sales Price by Application (2027-2032) & (USD/ml) Table 183. Asia PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 184. Asia PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 185. Asia PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 186. Asia PD-1 and PD-L1 Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (L) Table 187. Asia PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 188. Asia PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 189. Asia PD-1 and PD-L1 Inhibitors Sales Price by Country (2021-2026) & (USD/ml) Table 190. Asia PD-1 and PD-L1 Inhibitors Sales Price by Country (2027-2032) & (USD/ml) Table 191. Japan PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 192. South Korea PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 193. India PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 194. Australia PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 195. Taiwan PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 196. Southeast Asia PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 197. SAMEA PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 198. SAMEA PD-1 and PD-L1 Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 199. SAMEA PD-1 and PD-L1 Inhibitors Sales by Type (2021-2026) & (L) Table 200. SAMEA PD-1 and PD-L1 Inhibitors Sales by Type (2027-2032) & (L) Table 201. SAMEA PD-1 and PD-L1 Inhibitors Sales Price by Type (2021-2026) & (USD/ml) Table 202. SAMEA PD-1 and PD-L1 Inhibitors Sales Price by Type (2027-2032) & (USD/ml) Table 203. SAMEA PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 204. SAMEA PD-1 and PD-L1 Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 205. SAMEA PD-1 and PD-L1 Inhibitors Sales by Application (2021-2026) & (L) Table 206. SAMEA PD-1 and PD-L1 Inhibitors Sales by Application (2027-2032) & (L) Table 207. SAMEA PD-1 and PD-L1 Inhibitors Sales Price by Application (2021-2026) & (USD/ml) Table 208. SAMEA PD-1 and PD-L1 Inhibitors Sales Price by Application (2027-2032) & (USD/ml) Table 209. SAMEA PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 210. SAMEA PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 211. SAMEA PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 212. SAMEA PD-1 and PD-L1 Inhibitors Sales by Country (2021 VS 2025 VS 2032) & (L) Table 213. SAMEA PD-1 and PD-L1 Inhibitors Sales by Country (2021-2026) & (L) Table 214. SAMEA PD-1 and PD-L1 Inhibitors Sales by Country (2027-2032) & (L) Table 215. SAMEA PD-1 and PD-L1 Inhibitors Sales Price by Country (2021-2026) & (USD/ml) Table 216. SAMEA PD-1 and PD-L1 Inhibitors Sales Price by Country (2027-2032) & (USD/ml) Table 217. Brazil PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 218. Argentina PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 219. Chile PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 220. Colombia PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 221. Peru PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 222. Saudi Arabia PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 223. Israel PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 224. UAE PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 225. Turkey PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 226. Iran PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 227. Egypt PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Table 228. Key Raw Materials Table 229. Raw Materials Key Suppliers Table 230. PD-1 and PD-L1 Inhibitors Distributors List Table 231. PD-1 and PD-L1 Inhibitors Customers List Table 232. Research Programs/Design for This Report Table 233. Authors List of This Report Table 234. Secondary Sources Table 235. Primary Sources List of Figures Figure 1. PD-1 and PD-L1 Inhibitors Image Figure 2. Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1 and PD-L1 Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 4. PD-1 Inhibitors Image Figure 5. PD-L1 Inhibitors Image Figure 6. Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global PD-1 and PD-L1 Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 8. Solid Tumors Image Figure 9. Blood-related Tumors Image Figure 10. Global PD-1 and PD-L1 Inhibitors Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global PD-1 and PD-L1 Inhibitors Revenue (2021-2032) & (US$ Million) Figure 12. Global PD-1 and PD-L1 Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2021-2032) Figure 15. Global PD-1 and PD-L1 Inhibitors Sales (2021-2032) & (L) Figure 16. Global PD-1 and PD-L1 Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (L) Figure 17. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico PD-1 and PD-L1 Inhibitors Sales YoY (2021-2032) & (L) Figure 19. Europe PD-1 and PD-L1 Inhibitors Sales YoY (2021-2032) & (L) Figure 20. China PD-1 and PD-L1 Inhibitors Sales YoY (2021-2032) & (L) Figure 21. Asia (Excluding China) PD-1 and PD-L1 Inhibitors Sales YoY (2021-2032) & (L) Figure 22. South America, Middle East and Africa PD-1 and PD-L1 Inhibitors Sales YoY (2021-2032) & (L) Figure 23. Global PD-1 and PD-L1 Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global PD-1 and PD-L1 Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2021-2032) Figure 29. Global PD-1 and PD-L1 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (L) Figure 30. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2021-2032) Figure 32. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2021-2032) Figure 35. Global PD-1 and PD-L1 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (L) Figure 36. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2021-2032) Figure 38. North America PD-1 and PD-L1 Inhibitors Revenue Share by Type (2021-2032) Figure 39. North America PD-1 and PD-L1 Inhibitors Sales Share by Type (2021-2032) Figure 40. North America PD-1 and PD-L1 Inhibitors Revenue Share by Application (2021-2032) Figure 41. North America PD-1 and PD-L1 Inhibitors Sales Share by Application (2021-2032) Figure 42. North America PD-1 and PD-L1 Inhibitors Revenue Share by Country (2021-2032) Figure 43. North America PD-1 and PD-L1 Inhibitors Sales Share by Country (2021-2032) Figure 44. Europe PD-1 and PD-L1 Inhibitors Revenue Share by Type (2021-2032) Figure 45. Europe PD-1 and PD-L1 Inhibitors Sales Share by Type (2021-2032) Figure 46. Europe PD-1 and PD-L1 Inhibitors Revenue Share by Application (2021-2032) Figure 47. Europe PD-1 and PD-L1 Inhibitors Sales Share by Application (2021-2032) Figure 48. Europe PD-1 and PD-L1 Inhibitors Revenue Share by Country (2021-2032) Figure 49. Europe PD-1 and PD-L1 Inhibitors Sales Share by Country (2021-2032) Figure 50. China PD-1 and PD-L1 Inhibitors Revenue Share by Type (2021-2032) Figure 51. China PD-1 and PD-L1 Inhibitors Sales Share by Type (2021-2032) Figure 52. China PD-1 and PD-L1 Inhibitors Revenue Share by Application (2021-2032) Figure 53. China PD-1 and PD-L1 Inhibitors Sales Share by Application (2021-2032) Figure 54. Asia PD-1 and PD-L1 Inhibitors Revenue Share by Type (2021-2032) Figure 55. Asia PD-1 and PD-L1 Inhibitors Sales Share by Type (2021-2032) Figure 56. Asia PD-1 and PD-L1 Inhibitors Revenue Share by Application (2021-2032) Figure 57. Asia PD-1 and PD-L1 Inhibitors Sales Share by Application (2021-2032) Figure 58. Asia PD-1 and PD-L1 Inhibitors Revenue Share by Country (2021-2032) Figure 59. Asia PD-1 and PD-L1 Inhibitors Sales Share by Country (2021-2032) Figure 60. SAMEA PD-1 and PD-L1 Inhibitors Revenue Share by Type (2021-2032) Figure 61. SAMEA PD-1 and PD-L1 Inhibitors Sales Share by Type (2021-2032) Figure 62. SAMEA PD-1 and PD-L1 Inhibitors Revenue Share by Application (2021-2032) Figure 63. SAMEA PD-1 and PD-L1 Inhibitors Sales Share by Application (2021-2032) Figure 64. SAMEA PD-1 and PD-L1 Inhibitors Revenue Share by Country (2021-2032) Figure 65. SAMEA PD-1 and PD-L1 Inhibitors Sales Share by Country (2021-2032) Figure 66. PD-1 and PD-L1 Inhibitors Value Chain Figure 67. Manufacturing Cost Structure Figure 68. PD-1 and PD-L1 Inhibitors Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
Applications
  • Solid Tumors
  • Blood-related Tumors
Companies covered
  • Merck
  • Bristol-Myers Squibb
  • Roche
  • AstraZeneca
  • Ono Pharmaceutical
  • Regeneron
  • Innovent
  • Hengrui Medicine
  • Junshi Biosciences
  • Merck KGaA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 PD-1 and PD-L1 Inhibitors Market by Type
  3. 1.2.1 Global PD-1 and PD-L1 Inhibitors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 PD-1 Inhibitors
  5. 1.2.3 PD-L1 Inhibitors
  6. 1.3 PD-1 and PD-L1 Inhibitors Market by Application
  7. 1.3.1 Global PD-1 and PD-L1 Inhibitors Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Solid Tumors
  9. 1.3.3 Blood-related Tumors
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 PD-1 and PD-L1 Inhibitors Market Dynamics
  1. 2.1 PD-1 and PD-L1 Inhibitors Industry Trends
  2. 2.2 PD-1 and PD-L1 Inhibitors Industry Drivers
  3. 2.3 PD-1 and PD-L1 Inhibitors Industry Opportunities and Challenges
  4. 2.4 PD-1 and PD-L1 Inhibitors Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global PD-1 and PD-L1 Inhibitors Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Region
  3. 3.2.1 Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global PD-1 and PD-L1 Inhibitors Revenue by Region (2021-2026)
  5. 3.2.3 Global PD-1 and PD-L1 Inhibitors Revenue by Region (2027-2032)
  6. 3.2.4 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2021-2032)
  7. 3.3 Global PD-1 and PD-L1 Inhibitors Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global PD-1 and PD-L1 Inhibitors Sales by Region
  9. 3.4.1 Global PD-1 and PD-L1 Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global PD-1 and PD-L1 Inhibitors Sales by Region (2021-2026)
  11. 3.4.3 Global PD-1 and PD-L1 Inhibitors Sales by Region (2027-2032)
  12. 3.4.4 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers
  2. 4.1.1 Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global PD-1 and PD-L1 Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers
  6. 4.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global PD-1 and PD-L1 Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global PD-1 and PD-L1 Inhibitors Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global PD-1 and PD-L1 Inhibitors Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global PD-1 and PD-L1 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global PD-1 and PD-L1 Inhibitors Manufacturers, Product Type & Application
  13. 4.7 Global PD-1 and PD-L1 Inhibitors Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global PD-1 and PD-L1 Inhibitors Market CR5 and HHI
  16. 4.8.2 2025 PD-1 and PD-L1 Inhibitors Tier 1, Tier 2, and Tier 3
5 PD-1 and PD-L1 Inhibitors Market by Type
  1. 5.1 Global PD-1 and PD-L1 Inhibitors Revenue by Type
  2. 5.1.1 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2021-2032)
  5. 5.2 Global PD-1 and PD-L1 Inhibitors Sales by Type
  6. 5.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PD-1 and PD-L1 Inhibitors Sales by Type (2021-2032) & (L)
  8. 5.2.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2021-2032)
  9. 5.3 Global PD-1 and PD-L1 Inhibitors Price by Type
6 PD-1 and PD-L1 Inhibitors Market by Application
  1. 6.1 Global PD-1 and PD-L1 Inhibitors Revenue by Application
  2. 6.1.1 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2021-2032)
  5. 6.2 Global PD-1 and PD-L1 Inhibitors Sales by Application
  6. 6.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global PD-1 and PD-L1 Inhibitors Sales by Application (2021-2032) & (L)
  8. 6.2.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2021-2032)
  9. 6.3 Global PD-1 and PD-L1 Inhibitors Price by Application
7 Company Profiles
  1. 7.1 Merck
  2. 7.1.1 Merck Company Information
  3. 7.1.2 Merck Business Overview
  4. 7.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Merck PD-1 and PD-L1 Inhibitors Product Portfolio
  6. 7.1.5 Merck Recent Developments
  7. 7.2 Bristol-Myers Squibb
  8. 7.2.1 Bristol-Myers Squibb Company Information
  9. 7.2.2 Bristol-Myers Squibb Business Overview
  10. 7.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio
  12. 7.2.5 Bristol-Myers Squibb Recent Developments
  13. 7.3 Roche
  14. 7.3.1 Roche Company Information
  15. 7.3.2 Roche Business Overview
  16. 7.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Roche PD-1 and PD-L1 Inhibitors Product Portfolio
  18. 7.3.5 Roche Recent Developments
  19. 7.4 AstraZeneca
  20. 7.4.1 AstraZeneca Company Information
  21. 7.4.2 AstraZeneca Business Overview
  22. 7.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio
  24. 7.4.5 AstraZeneca Recent Developments
  25. 7.5 Ono Pharmaceutical
  26. 7.5.1 Ono Pharmaceutical Company Information
  27. 7.5.2 Ono Pharmaceutical Business Overview
  28. 7.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio
  30. 7.5.5 Ono Pharmaceutical Recent Developments
  31. 7.6 Regeneron
  32. 7.6.1 Regeneron Company Information
  33. 7.6.2 Regeneron Business Overview
  34. 7.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio
  36. 7.6.5 Regeneron Recent Developments
  37. 7.7 Innovent
  38. 7.7.1 Innovent Company Information
  39. 7.7.2 Innovent Business Overview
  40. 7.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Innovent PD-1 and PD-L1 Inhibitors Product Portfolio
  42. 7.7.5 Innovent Recent Developments
  43. 7.8 Hengrui Medicine
  44. 7.8.1 Hengrui Medicine Company Information
  45. 7.8.2 Hengrui Medicine Business Overview
  46. 7.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio
  48. 7.8.5 Hengrui Medicine Recent Developments
  49. 7.9 Junshi Biosciences
  50. 7.9.1 Junshi Biosciences Company Information
  51. 7.9.2 Junshi Biosciences Business Overview
  52. 7.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio
  54. 7.9.5 Junshi Biosciences Recent Developments
  55. 7.10 Merck KGaA
  56. 7.10.1 Merck KGaA Company Information
  57. 7.10.2 Merck KGaA Business Overview
  58. 7.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio
  60. 7.10.5 Merck KGaA Recent Developments
8 North America
  1. 8.1 North America PD-1 and PD-L1 Inhibitors Market Size by Type
  2. 8.1.1 North America PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2032)
  3. 8.1.2 North America PD-1 and PD-L1 Inhibitors Sales by Type (2021-2032)
  4. 8.1.3 North America PD-1 and PD-L1 Inhibitors Price by Type (2021-2032)
  5. 8.2 North America PD-1 and PD-L1 Inhibitors Market Size by Application
  6. 8.2.1 North America PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2032)
  7. 8.2.2 North America PD-1 and PD-L1 Inhibitors Sales by Application (2021-2032)
  8. 8.2.3 North America PD-1 and PD-L1 Inhibitors Price by Application (2021-2032)
  9. 8.3 North America PD-1 and PD-L1 Inhibitors Market Size by Country
  10. 8.3.1 North America PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America PD-1 and PD-L1 Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America PD-1 and PD-L1 Inhibitors Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe PD-1 and PD-L1 Inhibitors Market Size by Type
  2. 9.1.1 Europe PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2032)
  3. 9.1.2 Europe PD-1 and PD-L1 Inhibitors Sales by Type (2021-2032)
  4. 9.1.3 Europe PD-1 and PD-L1 Inhibitors Price by Type (2021-2032)
  5. 9.2 Europe PD-1 and PD-L1 Inhibitors Market Size by Application
  6. 9.2.1 Europe PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2032)
  7. 9.2.2 Europe PD-1 and PD-L1 Inhibitors Sales by Application (2021-2032)
  8. 9.2.3 Europe PD-1 and PD-L1 Inhibitors Price by Application (2021-2032)
  9. 9.3 Europe PD-1 and PD-L1 Inhibitors Market Size by Country
  10. 9.3.1 Europe PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe PD-1 and PD-L1 Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe PD-1 and PD-L1 Inhibitors Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China PD-1 and PD-L1 Inhibitors Market Size by Type
  2. 10.1.1 China PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2032)
  3. 10.1.2 China PD-1 and PD-L1 Inhibitors Sales by Type (2021-2032)
  4. 10.1.3 China PD-1 and PD-L1 Inhibitors Price by Type (2021-2032)
  5. 10.2 China PD-1 and PD-L1 Inhibitors Market Size by Application
  6. 10.2.1 China PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2032)
  7. 10.2.2 China PD-1 and PD-L1 Inhibitors Sales by Application (2021-2032)
  8. 10.2.3 China PD-1 and PD-L1 Inhibitors Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia PD-1 and PD-L1 Inhibitors Market Size by Type
  2. 11.1.1 Asia PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2032)
  3. 11.1.2 Asia PD-1 and PD-L1 Inhibitors Sales by Type (2021-2032)
  4. 11.1.3 Asia PD-1 and PD-L1 Inhibitors Price by Type (2021-2032)
  5. 11.2 Asia PD-1 and PD-L1 Inhibitors Market Size by Application
  6. 11.2.1 Asia PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2032)
  7. 11.2.2 Asia PD-1 and PD-L1 Inhibitors Sales by Application (2021-2032)
  8. 11.2.3 Asia PD-1 and PD-L1 Inhibitors Price by Application (2021-2032)
  9. 11.3 Asia PD-1 and PD-L1 Inhibitors Market Size by Country
  10. 11.3.1 Asia PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia PD-1 and PD-L1 Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia PD-1 and PD-L1 Inhibitors Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA PD-1 and PD-L1 Inhibitors Market Size by Type
  2. 12.1.1 SAMEA PD-1 and PD-L1 Inhibitors Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA PD-1 and PD-L1 Inhibitors Sales by Type (2021-2032)
  4. 12.1.3 SAMEA PD-1 and PD-L1 Inhibitors Price by Type (2021-2032)
  5. 12.2 SAMEA PD-1 and PD-L1 Inhibitors Market Size by Application
  6. 12.2.1 SAMEA PD-1 and PD-L1 Inhibitors Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA PD-1 and PD-L1 Inhibitors Sales by Application (2021-2032)
  8. 12.2.3 SAMEA PD-1 and PD-L1 Inhibitors Price by Application (2021-2032)
  9. 12.3 SAMEA PD-1 and PD-L1 Inhibitors Market Size by Country
  10. 12.3.1 SAMEA PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA PD-1 and PD-L1 Inhibitors Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA PD-1 and PD-L1 Inhibitors Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 PD-1 and PD-L1 Inhibitors Value Chain Analysis
  2. 13.1.1 PD-1 and PD-L1 Inhibitors Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 PD-1 and PD-L1 Inhibitors Production Mode & Process
  6. 13.2 PD-1 and PD-L1 Inhibitors Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 PD-1 and PD-L1 Inhibitors Distributors
  9. 13.2.3 PD-1 and PD-L1 Inhibitors Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst